We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

RNA Sequencing Assay Gains EU Certification for Solid Tumor Profiling

By LabMedica International staff writers
Posted on 27 Oct 2026

Genomic profiling of solid tumors supports clinical management by detecting gene rearrangements and specific splice variants. Combining RNA and DNA testing can identify more clinically actionable gene fusions than DNA testing alone. To support these workflows, a newly certified assay provides an RNA sequencing option under European diagnostic regulation.

The Tempus xR assay from Tempus AI, Inc. (Chicago, IL, USA) has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. Designed for solid tumor tissue analysis, the assay supports cancer genomic profiling for clinical management. The certification also covers Tempus’ quality management system for next-generation sequencing devices used in this setting.


Photo courtesy of Tempus AI
Photo courtesy of Tempus AI

Within this profiling workflow, xR detects gene rearrangements and specific splice variants in solid tumor tissue using RNA sequencing as part of a next-generation sequencing approach. Evidence supporting the combination of RNA and DNA analysis comes from a published study cited for the assay, which showed that combined Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone.

The IVDR certification supports continued access to xR in the European Union beyond 2028. That year is the transition deadline for eligible legacy Class C devices. The certification also provides biopharma partners with an IVDR-certified testing platform to support clinical studies.

“Securing our European IVDR certification for xR reinforces our commitment to meeting the highest regulatory standards globally. This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region,” said Lauren Silvis, SVP of External Affairs at Tempus.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Urinalysis Solution
UN-9000
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Latest Molecular Diagnostics News

Fapon Showcases AI-Engineered Enzymes and RNA Workflows at AMP 2026
27 Oct 2026  |   Molecular Diagnostics

AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
27 Oct 2026  |   Molecular Diagnostics

Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
27 Oct 2026  |   Molecular Diagnostics